SnapGene
About SnapGene
As the PI of an academic lab, Ben Glick was frustrated by the huge amount of effort being wasted during cloning. Researchers made avoidable mistakes when planning their cloning procedures, and records of cloning procedures were incomplete. In the 21st century, many molecular biologists still didn't know the full properties of the DNA molecules they were using.He also perceived the solution: good software. If molecular biology software were easier to use than pen and paper, researchers would naturally plan their cloning procedures with computers, and electronic records could be automatically produced.To achieve this goal, he brought together a group of scientists, software engineers, usability experts, and product developers. The company won Phase I and II SBIR grants from the NIH to develop SnapGene. Working with labs around the world, we created software to meet the everyday needs of molecular biologists. Each enhancement has generated new ideas, and SnapGene is still in active development, evolving as the field is changing.In 2022, SnapGene became part of Dotmatics, the world's largest and most powerful scientific R&D software platform. Combining an open data informatics framework with best in breed applications like SnapGene, we offer the first true end-to-end solutions for biology, chemistry, formulations, data management, flow cytometry, and more. Together, our company can better: connect science, data, and decision-making and ultimately drive meaningful transformation for our customers.
Company Metrics
- Employees: 1-10
- Monthly Visits: None
- Tech Stack: None active products
Financial Information
- Estimated Revenue: $1M to $10M
- Total Funding: None None
- Last Funding: None None (None)
- Funding Status: None
Technology Stack
SnapGene actively uses None products in their tech stack.
Market Presence
Industries: Research, Research, Biotechnology research
Headquarters: Chicago, Illinois